FIG. 1




A
Col 1a1
Col1a1 (fold change from sham)
250
200
150
100
50
0
***
*
sham
PBS-UUO (SC)
36232
36234
36235
36237
36328
Treatment
B
Col 3a1
Col3a1 (fold change from sham)
400
300
200
100
0
**
**
sham
PBS-UUO (SC)
36232
36234
36235
36237
36328
Treatment

FIG. 2

A


Col1A1
Col1a1 expression
150
100
50
0
**
***
Sham
PBS-UUO
36282
36283
36284
36285
Treatment groups

B




Co3A1
Col3a1 expression
150
100
50
0
**
***
Sham
PBS-UUO
36282
36283
36284
36285
Treatment groups

FIG. 3

A


Col1A1
DAM11-39
Col1a1 expression
500
400
300
200
100
0
***
***
*
Sham
PBS-UUO
25220
25221
25923
Treatment groups

B





Col3A1
DAM11-39
Col3a1 expression
500
400
300
200
100
0
***
**
***
Sham
PBS-UUO
25220
25221
25923
Treatment groups

FIG. 4

A


Col1a1
Fold change
150
100
50
0
*
*
sham
IRI-PBS
36328
36232
Treatments

B


Col3a1
Fold change
150
100
50
0
*
sham
IRI-PBS
36328
36232
Treatments

C




Collagen Area Fraction
Collagen Area Fraction (%)
15
10
5
0
***
***
Sham
IRI+PBS
36328
36232

FIG. 5

A


Urinary ACR (mg/gCr)
Albumin to Creatinine ratio
1000
100
10
1
**
Nx-ctrl
IRnx-PBS
25109
36328

B



Urinary ACR (mg/gCr)
Albumin to Creatinine ratio
1000
100
10
1
**
Nx-ctrl
IRNx-PBS
36284

FIG. 5

C




Urinary ACR (mg/gCr)
Albumin to Creatinine ratio
1000
100
10
1
***
Nx-ctrl
IRNx-PBS
25220

FIG. 6

A


anti-miR-21 activity
Luciferase (Fold Change)
50
40
30
20
10
0
0.01
0.1
1
10
100
1000
Concentration (nM)
36731
36842
36843
36844
36845
36846
36847
36039

B





120
100
80
60
40
20
0
-20
0
50nM
100nM
250nM
500nM
1uM
2uM
36965
36967
36731
36846
25220
36847

FIG. 7

A


Col1a1
Fold Change (from Sham)
150
100
50
0
*
*
PBS
36055
36847
36731
Treatment groups

B


Col3A1
Fold Change (from Sham)
150
100
50
0
**
**
PBS
36055
36847
36731
Treatment groups